Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...

The company has formed strategic partnerships with Metsera, according to Truist Securities, and launched CREXONT®, a novel treatment for Parkinson's disease. Moreover, Amneal has received FDA ...

The company has formed strategic partnerships with Metsera, according to Truist Securities, and launched CREXONT®, a novel treatment for Parkinson's disease. Moreover, Amneal has received FDA approval ...

The project will also feature investments from US biotech firm Metsera in addition to fiscal incentives from the Gujarat government. "So, the total project size could reach up to $250 million to $300 ...

The company will develop and supply a portfolio of next-generation branded medicines for metabolic diseases and obesity, including GLP-1 and amylin receptor agonists, in collaboration with Metsera.

The earnings call came amid a summer of competitive trial results, with more to come long after the investor call ended. Metsera, Terns Pharmaceuticals and Viking Therapeutics have all been making ...